Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine, Mount Sinai, New York, NYDeepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI, is Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System.
After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his science degree as a National Merit Scholar at MIT. He received his MD from Cornell and MPH from Harvard. He is working on his Executive MBA from Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, Associate Professor of Medicine, Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He then served as the Chief of Cardiology at VA Boston Healthcare System and subsequently as Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital. He was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women's Hospital as the 2014 Eugene Braunwald Scholar. He received the Research Mentor Award from Brigham and Women's Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women's Hospital in 2017, ACC's Distinguished Mentor Award in 2018, AHA's Distinguished Scientist Award in 2019, NLA's Honorary Lifetime Membership Award in 2021, and SCAI's Master designation in 2022.
Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2022. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald's Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-Editors of Braunwald's Heart Disease. He had served as Senior Associate Editor for News and Clinical Trials for ACC.org and is the Editor of the Journal of Invasive Cardiology. He was the PI for CHARISMA, CRESCENDO, COGENT, REDUCE-IT, SOLOIST, SCORED, and ENTRIGUE and co-PI of the three CHAMPION trials, STAMPEDE, SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, THEMIS-PCI, and the REACH registry. In 2014, he was listed in the AHA/ASA top advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial by NEJM; in 2020 and again in 2021, SOLOIST and SCORED were listed by the AHA. He was the inaugural Chair of the AHA-GWTG Quality Oversight Committee and served as a Trustee of the ACC, and currently serves on the Board of Directors of the AHA New York City chapter.
Disclosures
Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys; Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock); Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo.
Recent Contributions to PracticeUpdate:
- PCSK9 Inhibitors for Acute Coronary Syndrome
- Preoperatively Diagnosed Patent Foramen Ovale Is Associated With Perioperative Ischemic Stroke
- Association of Different Antiplatelet Therapies With Mortality After Primary PCI
- Combining Proton Pump Inhibitors and Thienopyridines Increases Risk for Stroke and Myocardial Infarction
- Quality of Life After Everolimus-Eluting Stents or Bypass Surgery for Left Main Disease
- 2017 Top Stories in Cardiology: The COMPASS Trial
- Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease
- Similar Benefits From Below-Target and Target Dose Enalapril in Patients With Heart Failure
- Guided De-Escalation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing PCI
- Combined Main Renal Artery Plus Branch Renal Denervation Effective in Patients With Resistant Hypertension